Ergebnisse aus randomisierter, doppelt verblindeter Phase-I/II-Studie von XBiotech deuten auf mögliche bahnbrechende Behandlung gegen...
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer...
XBiotech beginnt mit dem Bau der neuen F&E-Anlage auf seinem 19 Hektar großen Campus AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE...
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc...
Le Dr Alan Kivitz prend la tête du programme Natrunix, conduit par XBiotech dans le traitement de la polyarthrite rhumatoïde (L’étude...
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis (Phase II Multicenter Study is Proceeding Well with High...
XBiotech annonce l'achèvement du recrutement dans son essai clinique de phase I concernant Hutrukin, un nouveau traitement candidat pour...
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke AUSTIN, Texas, Sept...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.